Related references
Note: Only part of the references are listed.Cardiac Imaging in Childhood Cancer Survivors: A State-of-the-Art Review
Massimiliano Camilli et al.
CURRENT PROBLEMS IN CARDIOLOGY (2023)
ESC 2022 guidelines on cardio-oncology in collaboration with the European Hematology Association (EHA), European Society of Therapeutic Radiology and Oncology (ESTRO) and International Cardio-Oncology Society (IC- OS) developed by the Cardio-Oncology Task Force of the European Society of Cardiology (ESC)
Alexander R. Lyon et al.
GIORNALE ITALIANO DI CARDIOLOGIA (2023)
Incessant Pericarditis Successfully Treated With Anakinra in a Patient on Active Treatment for Mediastinal Lymphoma
Massimiliano Camilli et al.
CANADIAN JOURNAL OF CARDIOLOGY (2022)
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC)
Alexander R. Lyon et al.
EUROPEAN HEART JOURNAL (2022)
Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy
Emma C. Morris et al.
NATURE REVIEWS IMMUNOLOGY (2022)
CAR-T cell: Toxicities issues: Mechanisms and clinical management
Florent Wallet et al.
BULLETIN DU CANCER (2021)
Pathophysiology of sepsis-induced cardiomyopathy
Steven M. Hollenberg et al.
NATURE REVIEWS CARDIOLOGY (2021)
Adverse Cardiovascular and Pulmonary Events Associated With Chimeric Antigen Receptor T-Cell Therapy
Adam Goldman et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Nikhil C. Munshi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Cytokine Release Syndrome Biology and Management
Dustin A. Cobb et al.
CANCER JOURNAL (2021)
Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies
Alan H. Baik et al.
CIRCULATION RESEARCH (2021)
CAR-T cell therapy: current limitations and potential strategies
Robert C. Sterner et al.
BLOOD CANCER JOURNAL (2021)
Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia
John E. Levine et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Cardiotoxicity Associated with Anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Recognition, Risk Factors, and Management
Ethan A. Burns et al.
DISEASES (2021)
Cardiac Events Associated With Chimeric Antigen Receptor T-Cells (CAR-T) A VigiBase Perspective
Joe-Elie Salem et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
Michael Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications
Yuanyuan Zhang et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2020)
Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies
Craig W. Freyer et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies
Haneen Shalabi et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Chimeric Antigen Receptor T-Cell Therapy-Associated Cardiomyopathy in Patients With Refractory or Relapsed Non-Hodgkin Lymphoma
Sarju Ganatra et al.
CIRCULATION (2020)
Cardiovascular Effects of CAR T Cell Therapy A Retrospective Study
Benedicte Lefebvre et al.
JACC: CARDIOONCOLOGY (2020)
Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management
Martina Pennisi et al.
BLOOD ADVANCES (2020)
CAR-T efficacy: is conditioning the key?
Sattva S. Neelapu
BLOOD (2019)
CAR T cell therapy: A new era for cancer treatment
Rimjhim Mohanty et al.
ONCOLOGY REPORTS (2019)
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts
Rosalie M. Sterner et al.
BLOOD (2019)
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Frederick L. Locke et al.
LANCET ONCOLOGY (2019)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Chimeric Antigen Receptor T-Cell Therapy for Cancer and Heart JACC Council Perspectives
Sarju Ganatra et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T)
Raza M. Alvi et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer
Yanjing Li et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Cardiac Profile of Chimeric Antigen Receptor T Cell Therapy in Children: A Single-Institution Experience
Danielle S. Burstein et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
David Porter et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
Margherita Norelli et al.
NATURE MEDICINE (2018)
CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
Theodoros Giavridis et al.
NATURE MEDICINE (2018)
Chimeric Antigen Receptor Therapy
Carl H. June et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Jae H. Park et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome
Robert Q. Le et al.
ONCOLOGIST (2018)
Cardiotoxicity of Immunotherapy: Incidence, Diagnosis, and Management
Aarti Asnani
CURRENT ONCOLOGY REPORTS (2018)
Cytokine release syndrome
Alexander Shimabukuro-Vornhagen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains
Leah Alabanza et al.
MOLECULAR THERAPY (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia
Julie C. Fitzgerald et al.
CRITICAL CARE MEDICINE (2017)
Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease
Jennifer N. Brudno et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy
Hanren Dai et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy
Hanren Dai et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs
Soranobu Ninomiya et al.
BLOOD (2015)
Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
James N. Kochenderfer et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Daniel W. Lee et al.
LANCET (2015)
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
David L. Porter et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Current concepts in the diagnosis and management of cytokine release syndrome
Daniel W. Lee et al.
BLOOD (2014)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Marco L. Davila et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma
Gerald P. Linette et al.
BLOOD (2013)
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation
James N. Kochenderfer et al.
BLOOD (2013)
Increased intensity lymphodepletion and adoptive immunotherapy - how far can we go?
Pawel Muranski et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2006)
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells
L Gattinoni et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock
N Pathan et al.
LANCET (2004)